MedTrace Logo

SMS Turkey: Harnessing the Power of Text Messaging to Promote Smoking Cessation

NCT00912795 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2016-10-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to develop and test a text messaging-based smoking cessation program for adults who are currently smoking and want to quit, living in Turkey.

Conditions

  • Smoking

Interventions

BEHAVIORAL

SMS Turkey

6-week smoking cessation program delivered via daily text messages SMS Turkey: 6-week smoking cessation program delivered via text messaging. SMS Turkey content is guided by the Cognitive Behavioral Therapy (CBT) theory. Content was tailored based on participant's stage in quitting (i.e., pre-quit, quit day, early-quit, late-quit, relapse). Based on the typical relapse trajectory, content paths were created for participants based on whether or not they were smoking 2 days after quit day; and again at 7 days after quit day. Depending on the participant's content path, the total number of messages received ranged from 91 (for those assigned to the encouragement arm) to 146 (for those who relapsed and then were assigned to the late quit messages).

Sponsors & Collaborators

  • Hacettepe University

    collaborator OTHER

  • Fogarty International Center of the National Institute of Health

    collaborator NIH

  • Center for Innovative Public Health Research

    lead OTHER

Principal Investigators

  • Michele Ybarra, MPH PhD · Center for Innovative Public Health Research

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-09-30
Completion
2011-09-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00912795 on ClinicalTrials.gov